US Exchange Filings

CEL-SCI Receives Saudi Rare-Disease Designation for Multikine Cancer Immunotherapy

CEL-SCI says Saudi Arabia has granted its investigational cancer immunotherapy Multikine a rare-disease designation that could speed its review for marketing. The company and its Saudi partner, Amarox, plan to submit an application in the next two to three months, with a possible launch in 2027 or early 2028 if the treatment is approved.

The Saudi regulatory progress comes as Multikine faces a full clinical hold in the United States. The FDA has said it needs more information on product safety and manufacturing comparability before U.S. clinical studies can begin or resume.

Saudi regulatory and commercial plans

  • The Saudi Food and Drug Authority’s New Accelerator Program for Drugs in Rare Diseases designation makes Multikine eligible for priority review. The agency’s target assessment period is 160 working days; that is a review target, not an approval or guaranteed launch date.
  • CEL-SCI and Amarox are preparing a Saudi marketing application, which they expect to submit within two to three months. CEL-SCI says Saudi Arabia could become the treatment’s first commercial market, with initial sales potentially beginning in 2027 or early 2028, subject to approval.
  • Under a partnership announced in May, Amarox is CEL-SCI’s local regulatory representative and exclusive distributor in Saudi Arabia. The companies will split net revenue 50/50. Amarox’s in-country marketing, logistics and sales infrastructure is fully funded, according to the announcement.
  • The partnership includes an option to extend the commercial arrangement to other Gulf Cooperation Council countries: the United Arab Emirates, Kuwait, Qatar, Bahrain and Oman.
  • Multikine would initially be supplied from CEL-SCI’s U.S. manufacturing facility.
  • CEL-SCI plans to seek authorization for the same patient group as in its planned U.S. registration study: newly diagnosed, previously untreated adults with locally advanced, operable oral-cavity squamous cell cancer, no lymph-node involvement, and low or no tumor PD-L1 expression.
  • CEL-SCI cites results from its Phase 3 study in that patient group, reporting five-year survival of 73% with Multikine before standard treatment, compared with 45% with standard treatment alone. It also reports that the risk of death was 27% versus 55%. These are company-reported clinical results; Multikine remains investigational.

U.S. clinical hold

  • The FDA’s full clinical hold was communicated on September 17, and the agency sent a letter on October 5 explaining its concerns. CEL-SCI must provide the requested information and receive FDA notification before it can start or resume clinical studies under its U.S. investigational application.
  • The FDA cited insufficient information to assess risks to participants, including CEL-SCI’s proposed change to the residual host-cell DNA specification for the finished product and information about product quality and comparability after manufacturing-facility renovations.
  • CEL-SCI says the product currently meets the FDA’s requested specification and argues that its proposed change does not create a patient-safety risk. The company also says the post-renovation product is comparable to earlier batches. Those positions do not resolve the hold; the FDA’s requested information and notification are still required.

What changes for investors

The Saudi designation creates a potential route toward a first market while the U.S. clinical program remains on hold. It is a regulatory milestone, not marketing approval: CEL-SCI still needs to submit its Saudi application and obtain authorization before sales can begin. The company’s stated launch window therefore depends on the SFDA’s review and approval, while U.S. clinical work remains contingent on resolving the FDA’s concerns.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.